...
首页> 外文期刊>Journal of nanoscience and nanotechnology >Next generation adoptive immunotherapy - Human T cells as carriers of therapeutic nanoparticles
【24h】

Next generation adoptive immunotherapy - Human T cells as carriers of therapeutic nanoparticles

机译:下一代过继免疫疗法-人类T细胞作为治疗性纳米粒子的载体

获取原文
获取原文并翻译 | 示例

摘要

An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site. Here we suggest a new concept for a controlled inflammatory response in which the intrinsic cytotoxic properties of T cells are upgraded with the properties of nanoparticles transfected into the T cells during the ex vivo expansion process. We report in vitro upgrading of human T cells using PEGylated boron carbide nanoparticles functionalised with a translocation peptide aimed at Boron Neutron Capture Therapy (BNCT). A key finding is that the metabolism of such upgraded human T cells were not affected by a payload of 0.13 pg boron per cell and that the nanoparticles were retained in the cell population after several cell divisions. This is vital for transporting nanoparticles by T cells to the tumor site.
机译:一般而言,特别是就癌症治疗而言,过继免疫疗法中的重要步骤是在肿瘤部位引发炎症性T细胞应答。在这里,我们提出了一种控制炎症反应的新概念,其中,在离体扩增过程中,T细胞的固有细胞毒性特性随着转染到T细胞中的纳米颗粒的特性而得到了提升。我们报告了人类T细胞的体外升级,使用以硼中子俘获疗法(BNCT)为目标的易位肽功能化的聚乙二醇化碳化硼纳米粒子。一个关键发现是,这种升级的人类T细胞的代谢不受每个细胞0.13 pg硼的有效载荷的影响,并且纳米粒子在几次细胞分裂后仍保留在细胞群中。这对于通过T细胞将纳米颗粒运输到肿瘤部位至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号